| Name | Title | Contact Details |
|---|
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
JeNu Biosciences was founded by a leading Washington bio scientist and a medical technology entrepreneur. While working on an ultrasound device for topical drug delivery, they became curious about using ultrasound to improve cosmetic skin care product delivery. High energy ultrasound has been proven effective at pushing drugs through the skin, but in the process cells are damaged and high heat causes intense pain. But since cosmetics only need to be absorbed into the top layer of skin rather than through the skin like drugs they thought a low energy ultrasound device might work. After many attempts they proved that low energy ultrasound wouldn`t help on its own. At the same moment, they had the idea that lead to the JeNu System. Rather than using ultrasound energy to vibrate cells in the skin to open up pathways, what if they vibrated microspheres on the skin to open the pathways. This idea lead to patent application 20120271222 and JeNu Biosciences. Launched in 2009, JeNu spent close to $10MM and 5 years on research, development and engineering. JeNu Biosciences is now proud to present the JeNu System. It`s the first pain free, at home, quick way to increase absorption of your favorite skin care products. In just one minute per target area per day the JeNu system is clinically proven to increase absorption by up to 12 times, and improve the efficacy of skin care products by up to 40% in just 7 days.
ianacare is the best way for family caregivers to get the help and practical support they need (meals, rides, respite care, child care, pet care, house errands) from the people in their social circles, community, and co-workers who want to help. Get St...
AMRESCO is a Solon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lansinoh Laboratories Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Alexandria, VA. To find more information about Lansinoh Laboratories Inc, please visit www.lansinoh.com